Abstract 1946
Background
Bone marrow aspiration and biopsy at presentation is important to demonstrate the phase of the disease, to provide material for cytogenetic studies and to demonstrate the myelofibrosis, which have prognostic and therapeutic implications. In the current era of molecular diagnostics, the role of bone marrow examination is questionable. The present study was designed to identify the role of bone marrow examination on phase migration, karyotyping and myelofibrosis.
Methods
Data of newly diagnosed CML patients seen between January 2013 and June 2018 was retrospectively analysed. CML was confirmed by demonstration of BCR-ABL fusion gene by PCR or FISH. Patients were stratified into chronic phase (CP), accelerated phase (AP) and blast phase (BP) according to WHO diagnostic criteria (2016).
Results
Of 749 patients, 541 patients had evaluable data. The male female ratio was 1.52:1 The median age at presentation was 37 years (range, 9-80 years). According to EUTOS risk stratification, 406 (75.1%) patients were low risk and 135(24.9%) were high risk. Based on bone marrow blasts criterion, phase migration occurred in 16 (2.9%). Of these 16 patients, phase migration from CP to AP, CP to BP and AP to BP were seen in 8 (50%), 4(25%) and 4 (25%) patients, respectively. Data on karyotyping was available in 195 (36%) patients. Of 195 patients, additional cytogenetic abnormalities were detected in 30 (15.3%) which includes, major route abnormalities in 11 (5.6%) patients. Of these 11 patients, 6 patients were in CP, 4 patients were in AP and 1 patient in BP. Myelofibrosis was demonstrated in 264 (48.7%) patients of which grade 1, grade 2, grade 3 and grade 4 were seen in 72 (13.3%), 100 (18.5%), 70 (12.9%); 20 (3.7%) patients respectively.
Conclusions
Bone marrow examination at presentation in CML patients results in phase migration, provides adequate material for cytogenetic studies and demonstrates presence of myelofibrosis. Hence, bone marrow examination is indispensable in newly diagnosed CML patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nizam’s Institute of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract